Cytek Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	73.85	90.85	98.72	167.3	296.6	364.62
Short-Term Investments	188.16	170.68	179.15	95.11	44.55	-
Cash & Short-Term Investments	262	261.53	277.86	262.41	341.15	364.62
Cash Growth	-0.01%	-5.88%	5.89%	-23.08%	-6.44%	120.67%
Accounts Receivable	49.7	62.51	60.59	55.93	48.86	29.76
Other Receivables	1.6	9.62	-	0.19	2.01	-0.13
Receivables	51.3	72.13	60.59	56.12	50.88	29.63
Inventory	53.11	48.66	44.01	61.17	48.78	32.57
Prepaid Expenses	3.25	6.9	6.58	3.99	4.45	4.21
Restricted Cash	-	-	0.03	0.33	2.9	-
Other Current Assets	8.27	2.79	7.38	8.04	5.88	0.71
Total Current Assets	377.93	392	396.45	392.06	454.02	431.73
Property, Plant & Equipment	31.76	29.32	28.13	29.26	27.57	5.85
Long-Term Investments	-	1.6	-	-	-	-
Goodwill	16.69	16.7	16.66	16.18	10.14	10.14
Other Intangible Assets	14.87	16.82	20.13	23.08	4.33	4.74
Long-Term Deferred Tax Assets	-	-	33.37	30.49	20.46	9.17
Other Long-Term Assets	5.69	5.1	4.76	3.39	2.96	1.67
Total Assets	446.93	461.54	499.5	494.46	519.48	463.31

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	8.41	6.41	5.53	3.03	4.81	3.03
Accrued Expenses	25.43	25.18	21.69	18.99	20.42	14.89
Short-Term Debt	8.83	5.7	-	-	-	-
Current Portion of Long-Term Debt	0.6	0.6	4.66	0.57	0.58	-
Current Portion of Leases	3.27	2.88	3.76	2.44	2.93	-
Current Income Taxes Payable	3.36	3.07	1.52	1.3	0.25	2.48
Current Unearned Revenue	30.32	29.57	26.61	24.13	14.54	8.1
Other Current Liabilities	4.13	4.4	3.9	5.76	5.52	4.68
Total Current Liabilities	84.34	77.8	67.66	56.23	49.04	33.18
Long-Term Debt	0.25	0.53	1.05	1.65	2.27	-
Long-Term Leases	13.52	14.04	7.55	9.48	12.31	-
Long-Term Unearned Revenue	18.06	18.34	16.1	15.13	13.12	9.79
Other Long-Term Liabilities	8.82	9.09	11.4	18.91	17.18	14.95
Total Liabilities	124.98	119.8	103.76	101.39	93.93	57.92

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.13	0.13	0.13	0.13	0.14	0.13
Additional Paid-In Capital	451.85	441.11	430.79	423.39	442.89	423.63
Retained Earnings	-132.76	-101.74	-35.2	-29.18	-17.03	-19.61
Comprehensive Income & Other	2.74	2.24	0.02	-1.28	-0.7	0.9
Total Common Equity	321.95	341.74	395.74	393.06	425.3	405.04
Minority Interest	-	-	-	-	0.25	0.34
Shareholders' Equity	321.95	341.74	395.74	393.06	425.55	405.39
Total Liabilities & Equity	446.93	461.54	499.5	494.46	519.48	463.31

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	26.46	23.74	17.02	14.14	18.09	-
Net Cash (Debt)	235.54	237.79	260.85	248.27	323.06	364.62
Net Cash Growth	-1.17%	-8.84%	5.06%	-23.15%	-11.40%	124.44%
Net Cash Per Share	1.83	1.86	2.00	1.84	2.33	4.47
Filing Date Shares Outstanding	129.98	128.55	128.1	130.82	135.43	134.08
Total Common Shares Outstanding	129.98	128.55	129.21	130.71	135.37	133.75
Working Capital	293.6	314.19	328.78	335.83	404.98	398.55
Book Value Per Share	2.48	2.66	3.06	3.01	3.14	3.03
Tangible Book Value	290.4	308.22	358.95	353.8	410.82	390.16
Tangible Book Value Per Share	2.23	2.40	2.78	2.71	3.03	2.92
Buildings	8.16	7.92	7.76	7.65	5.55	-
Machinery	18.41	17.29	15.33	12.79	7.63	4.35
Construction In Progress	1.62	1.42	0.36	0.26	0.18	0.34
Leasehold Improvements	6.84	3.52	3.22	3.62	3.48	3.02

SEC Filings: 10-K · 10-Q